SCHEMBL19980628

SCHEMBL19980628

CCN1CC(c2cn(-c3ccc(F)cc3C(=O)N(C(C)C)C(C)C)c3cnccc23)C1

nearest known ligand 0.34

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 1/20 0.34
KDM4C Q9H3R0 3/20 0.33
HCRTR1 O43613 4/20 0.32
HCRTR2 O43614 4/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
PIM2 Q9P1W9 1/20 0.32
DRD2 P14416 1/20 0.32
SLC6A4 P31645 1/20 0.32
HRH2 P25021 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19980650 0.91 DRD2 (0.34) PTGDR2KDM4CHCRTR1HCRTR2MEN1
SCHEMBL19980685 0.88 KDM4C (0.36) PTGDR2KDM4CMEN1KMT2A
SCHEMBL26036581 0.88 RORC (0.34) PTGDR2KDM4CHCRTR1HCRTR2DRD2
SCHEMBL19972527 0.88 MEN1 (0.32) PTGDR2KDM4CHCRTR1HCRTR2MEN1
SCHEMBL23515871 0.86 KDM4C (0.36) PTGDR2KDM4CMEN1KMT2APIM2
SCHEMBL19972686 0.86 KDM4C (0.36) PTGDR2KDM4CMEN1KMT2APIM2
SCHEMBL19972688 0.86 KDM4C (0.36) PTGDR2KDM4CMEN1KMT2APIM2
SCHEMBL25135370 0.86 HTR6 (0.41) DRD2SLC6A4HRH2
SCHEMBL29985977 0.86 HTR6 (0.38) MEN1KMT2ADRD2SLC6A4
SCHEMBL19972555 0.86 HTR6 (0.38) MEN1KMT2ADRD2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4230627-A2 INHIBITORS OF THE MENIN-MLL INTERACTION Vitae Pharmaceuticals, LLC (US) 2023-08-23 EP disclosed
EP-3512850-B1 INHIBITORS OF THE MENIN-MLL INTERACTION VITAE PHARMACEUTICALS LLC (US) 2023-04-12 EP disclosed
WO-2018053267-A1 INHIBITORS OF THE MENIN-MLL INTERACTION VITAE PHARMACEUTICALS, INC. (US) 2018-03-22 WO disclosed